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Metastatic colorectalAbstract Purpose: The antiangiogenic agent aﬂibercept (ziv-aﬂibercept in the United States)
in combination with 5-ﬂuorouracil, leucovorin and irinotecan (FOLFIRI) signiﬁcantly
improved survival in a phase III study of patients with metastatic colorectal cancer (mCRC)
previously treated with an oxaliplatin-based regimen. In the present analysis, outcomes were
evaluated in prespeciﬁed subgroups to assess the consistency of the treatment effect.he 2012
oma de
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Performance status
Subgroup analysisMethods: Patients were randomised to receive FOLFIRI plus aﬂibercept or placebo every
2 weeks until disease progression or unacceptable toxicity occurred. Efﬁcacy and safety out-
comes were analysed with respect to demographic and baseline characteristics, and stratiﬁca-
tion factors (prior bevacizumab treatment and Eastern Cooperative Oncology Group
performance status).
Results: Median overall survival (OS, months [95.34% conﬁdence interval (CI)]) for aﬂiber-
cept versus placebo was 12.5 (10.8–15.5) versus 11.7 (9.8–13.8) in patients with prior bev-
acizumab treatment and 13.9 (12.7–15.6) versus 12.4 (11.2–13.5) in patients with no prior
bevacizumab treatment. The p value for interaction was 0.5668, indicating there was no het-
erogeneity in these subgroups. For OS and progression-free survival (PFS), there was a signif-
icantly greater beneﬁt (at the 2-sided 10% level) of treatment for patients with liver only
metastases versus patients with no liver metastases/liver metastases with other organ involve-
ment (p value for interaction: 0.0899 [OS]; 0.0076 [PFS]). There was no evidence of heteroge-
neity in treatment effect in any of the other subgroups examined.
Conclusions: The beneﬁts of aﬂibercept in combination with FOLFIRI in patients with
mCRC previously treated with oxaliplatin were maintained across the speciﬁed patient sub-
groups, including in patients with or without prior bevacizumab treatment.
 2013 The Authors. Published by Elsevier Ltd.Open access under CC BY license. 1. Introduction
The majority of patients (60%) with colorectal cancer
(CRC) have locally advanced or metastatic disease at
the time of diagnosis [1]. Prognosis for these patients
is poor, with a 5-year survival rate of approximately
12% [1]. However, the administration of molecularly tar-
geted agents in combination with standard chemother-
apy regimens has improved the outlook for patients
with metastatic CRC (mCRC).
Aﬂibercept (known as ziv-aﬂibercept in the U.S.,
and also known as VEGF Trap or AVE0005) is a
recombinant fusion protein containing vascular endo-
thelial growth factor (VEGF)-binding portions from
the extracellular domains of human VEGF receptors
1 and 2, fused to the Fc portion of human immuno-
globulin (Ig)G1. Aﬂibercept blocks the activity of
VEGFA, VEGFB and placental growth factor (PlGF),
by acting as a high-aﬃnity ligand trap to prevent these
ligands from binding to their endogenous receptors
[2,3].
Aﬂibercept is the ﬁrst targeted therapy to demon-
strate a statistically signiﬁcant and clinically meaningful
survival beneﬁt in patients previously treated with an
oxaliplatin-based regimen and receiving the irinotecan-
containing regimen FOLFIRI (5-ﬂuorouracil, leucovorin
and irinotecan) for the treatment of metastatic disease
[4]. The VELOUR (VEGF Trap (aﬂibercept) with irino-
tecan in colorectal cancer after failure of oxaliplatin
regimen) trial evaluated the eﬃcacy and safety of the
combination of aﬂibercept and FOLFIRI in patients
with mCRC, following disease progression while on or
after completion of treatment with an oxaliplatin-based
regimen. Adding aﬂibercept to FOLFIRI signiﬁcantly
improved overall survival (OS) relative to placebo plus
FOLFIRI (hazard ratio [HR], 0.817; 95.34% conﬁdence
interval [CI], 0.713–0.937; p = 0.0032), with mediansurvival times of 13.50 versus 12.06 months, respectively.
Aﬂibercept also signiﬁcantly improved progression-free
survival (PFS; HR, 0.758; 95% CI, 0.661–0.869;
p = 0.00007). Median PFS was 6.90 months for aﬂiber-
cept plus FOLFIRI and 4.67 months for placebo plus
FOLFIRI. The response rate in VELOUR was 19.8%
(95% CI, 16.4–23.2%) for aﬂibercept plus FOLFIRI
and 11.1% (95% CI, 8.5–13.8%) for placebo plus
FOLFIRI (p = 0.0001). No unexpected toxicities were
observed in the aﬂibercept plus FOLFIRI treatment
arm. As a consequence aﬂibercept was approved by
the U.S. Food and Drug Administration (FDA) in
August 2012 and by the European Medicines Agency
(EMA) in February 2013 for use in combination with
FOLFIRI in the treatment of patients with mCRC
who were resistant to or progressed following an
oxaliplatin-based regimen.
The purpose of this analysis of data from the
VELOUR trial was to assess the consistency of the ben-
eﬁt of aﬂibercept on OS and PFS by evaluating its eﬀect
in prespeciﬁed subgroups. Of particular interest was the
analysis of outcomes in patients stratiﬁed by prior bev-
acizumab treatment. In addition, the relationship
between patient demographics and baseline characteris-
tics and outcome was investigated.
2. Materials and methods
2.1. Patients and study design
Details of patient eligibility and the design of the
VELOUR study (a prospective multinational, random-
ised, double-blind, parallel-arm, phase III study [Clini-
calTrials.gov number, NCT00561470]) have been
reported previously [4]. Eligible patients were aged at
least 18 years; with an Eastern Cooperative Oncology
Group (ECOG) performance status (PS) score of 0–2.
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ven colorectal adenocarcinoma with metastatic disease
not amenable to potentially curative treatment. Patients
were required to have undergone a single prior oxalipl-
atin-containing chemotherapy regimen for metastatic
disease, with documented evidence of disease progres-
sion during or after treatment completion. Patients
who relapsed within 6 months of completion of oxalipl-
atin-based adjuvant therapy were also eligible for inclu-
sion. Prior bevacizumab was permitted, but not prior
irinotecan.
Eligible patients were randomised 1:1 to receive
FOLFIRI plus either aﬂibercept 4 mg/kg (aﬂibercept
arm) or placebo (control arm) every 2 weeks, with stratiﬁ-
cation according to prior bevacizumab treatment (yes/no)
and ECOG PS (0/1/2). Aﬂibercept or placebo was
administered intravenously (IV) over 1 h on day 1 of
each cycle, followed immediately by the FOLFIRI
regimen (irinotecan 180 mg/m2 IV over 90 min, with leu-
covorin 400 mg/m2 IV over 2 h, followed by 5-FU
400 mg/m2 bolus and 5-FU 2400 mg/m2 continuous
infusion over 46 h). Premedication with atropine and
anti-emetics was permitted. Granulocyte-colony stimu-
lating factor (G-CSF) was used according to the
American Society of Clinical Oncology guidelines [5].
Dose adjustments for each study treatment component
individually and/or cycle delays (up to 2 weeks) were
permitted in the event of toxicity. Patients were treated
until the occurrence of disease progression or unaccept-
able toxicity as judged by the physician. If FOLFIRI
was permanently discontinued, patients could continue
to receive aﬂibercept/placebo; if aﬂibercept/placebo
was permanently discontinued, patients could continue
to receive FOLFIRI. No crossover to aﬂibercept was
permitted after progression was documented in the
control arm.
At each treatment cycle, patients underwent clinical
examination and laboratory assessments (including uri-
nalysis) before receiving study treatment. Adverse events
(AEs) coded using The Medical Dictionary for Regula-
tory Activities (MedDRA) version 13.1, to provide a
system organ class (SOC) and preferred term (PT) for
each event and graded according to National Cancer
Institute Common Terminology Criteria for Adverse
Events v3.0, were recorded. Concomitant medications
were also recorded. Disease assessment was performed
every 6 weeks until documented progression. Response
was assessed according to Response Evaluation Criteria
In Solid Tumors (v1.0) [6] by a third party (independent
review committee, IRC), blinded to patient treatment.
2.2. Statistical analysis
The primary end-point of the study was OS, deﬁned
as the time interval from randomisation to death from
any cause. The cutoﬀ date for OS was the date of the
863rd event (7th February 2011). Secondary end-pointsincluded PFS, cutoﬀ date 6th May 2010, deﬁned as the
interval from randomisation to the ﬁrst observation of
disease progression according to IRC review, or death
from any cause; objective response (complete response
and partial response), and treatment-emergent adverse
events (TEAEs) and laboratory abnormalities.
Prespeciﬁed subgroups were deﬁned according to
demographic variables (age, gender, race, geographic
region), baseline characteristics (prior hypertension,
number of metastatic sites [IRC evaluation], liver metas-
tasis [IRC evaluation], location of primary tumour) and
stratiﬁcation factors at randomisation (ECOG PS, prior
bevacizumab treatment).
HRs andCI estimates for OS and PFS in the intention-
to-treat (ITT) population (all randomised patients) and
within each subgroup were estimated by a Cox propor-
tional hazards model [4]. Interactions between treatment
and each subgroup were tested at the 2-sided 10% level
(i.e. a p-value >0.1 indicates no evidence of heterogeneity
of treatment eﬀect across the subgroups for each factor).
Descriptive analysis of adverse events by treatment
arm was performed within each subgroup in the safety
population (patients who received at least one dose of
study treatment).
All ﬁnal analyses were conducted by Sanoﬁ
personnel.3. Results
Between November 2007 and March 2010, 1226
patients were randomised to receive, in combination
with FOLFIRI, either aﬂibercept (612 patients) or pla-
cebo (614 patients). Five patients in each treatment
arm were not treated and four patients randomised to
placebo received at least one administration of aﬂiber-
cept, therefore the safety population included 611
patients in the aﬂibercept arm and 605 in the control
arm (Fig. 1). At the cutoﬀ date for survival analysis
(7th February 2011), the median follow-up was
22.28 months.3.1. Eﬃcacy in demographic subgroups
OS and PFS in patients grouped by age, gender, race
and geographic region are shown in Figs. 2A and 3A.
For both eﬃcacy end-points, there was no signiﬁcant
treatment interaction between treatment groups and fac-
tors for any of the demographic subgroups examined. In
all subgroups, a treatment eﬀect in favour of the aﬂiber-
cept arm over the control arm (HR < 1.0) was seen for
both OS and PFS.3.2. Eﬃcacy in baseline characteristic subgroups
As shown in Figs. 2B and 3B, there was a signiﬁcantly
greater beneﬁt of treatment for patients with metastases
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• Other reasons (n=35)
Randomised (n=1226)
Allocated to FOLFIRI/aﬂibercept  (n=612)
• Received allocated intervenon (n=604)
• Did not receive allocated intervenon (n=8)
— 5 paents not treated (2 not eligible, 1 
PD, 1 withdrawn consent, 1 had no 
medical cover)
— 3 paents received ≥1 dose of placebo 
(dosing irregularies)
Disconnued intervenon  (n=598)
• Adverse events (n=74)
• Disease progression (n=437)
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Fig. 1. CONSORT diagram.
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tases or liver and metastases at other sites (OS:
p = 0.090; PFS: p = 0.008). A consistent treatment eﬀect
in favour of the aﬂibercept arm was seen for OS and
PFS for all subgroups (Figs. 2B and 3B). Of note a
revised classiﬁcation was used for the primary tumour
location (colon/rectosigmoid/other versus rectum). In
the previous presentations and using the three prespeci-
ﬁed primary tumour location categories of colon, recto-
sigmoid/other and rectum, patients with the location
rectosigmoid/other had a less favourable outcome for
OS with aﬂibercept (HR: 1.039 [0.7702, 1.4]).
3.3. Eﬃcacy by baseline stratiﬁcation factors (prior
bevacizumab treatment and ECOG PS)
Baseline characteristics for patients stratiﬁed by prior
bevacizumab treatment are shown in Table 1. Patients
with prior bevacizumab treatment comprised 30% of
the ITT population and the duration of bevacizumab
use as well as the antiangiogenic-free period were well
balanced between the control and aﬂibercept treatmentarms. For OS, there was no signiﬁcant interaction at
the 2-sided 10% level between treatment and stratiﬁca-
tion levels for prior bevacizumab treatment (yes versus
no; p = 0.5668) or ECOG PS (0 versus 1 versus 2;
p = 0.7231), and thus no evidence of heterogeneity in
treatment eﬀect (Table 2). A diﬀerence in favour of aﬂib-
ercept over placebo was observed in each stratiﬁcation
subgroup.
Survival outcomes by stratiﬁcation level of prior bev-
acizumab treatment are shown in Fig. 4. For patients
previously treated with bevacizumab, median OS was
12.5 months in the aﬂibercept arm and 11.7 months in
the control arm. Median OS in patients without prior
exposure to bevacizumab was 13.9 months in the aﬂiber-
cept arm and 12.4 months in the control arm.
The analysis of PFS by stratiﬁcation level also indi-
cated that there was no signiﬁcant interaction at the
2-sided 10% level between treatment and stratiﬁcation
levels for prior bevacizumab treatment (yes versus no;
p = 0.1958) or ECOG PS (0 versus 1 versus 2;
p = 0.6954) (Table 2). For patients who had received
prior bevacizumab, median PFS was 6.7 months in the
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Caucasian/White 1071 0.8 (0.691 to 0.925)
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Favours Placebo
Favours Placebo
Age >=65
Age <65
All patients
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Number of organs with metastasis <=1 535 0.767 (0.618 to 0.953)
Number of organs with metastasis >1 691 0.825 (0.692 to 0.982)
No liver metastasis,
or liver & other metastases
927 0.868 (0.742 to 1.015)
Liver metastasis only 299 0.649 (0.492 to 0.855)
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Hazard ratio
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Region: 0.653
Prior hypertension: 0.131
Number of organs
with metastasis: 0.699
Liver metastases only: 0.090
Location of primary tumour: 0.890
Cutoff date: 7 February 2011
HR, hazard ratio
A. Demographic subgroups
B. Baseline characteristics
Fig. 2. Forest plots for overall survival in planned subgroup analyses by patient demographic (Panel A) and baseline characteristics (Panel B). p
values 60.1 indicate a signiﬁcant interaction between treatment and demographic subgroup factors at the 2-sided 10% level (Cox proportional
hazard model). HR, hazard ratio.
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Subgroups N= HR (95% CI) Favours Aflibercept Favours Placebo
A. Demographic subgroups
B. Baseline characteristics
Cutoff date: 7 February 2011
HR, hazard ratio
Western Europe
All patients 1226 0.758 (0.661 to 0.869)
Age <65 783 0.765 (0.645 to 0.909)
Age >=65 443 0.748 (0.598 to 0.936)
Male 718 0.769 (0.645 to 0.917)
Female 508 0.733 (0.593 to 0.908)
425 0.778 (0.624 to 0.97)
Eastern Europe 297 0.688 (0.51 to 0.929)
North America 138 0.536 (0.344 to 0.837)
South America 118 0.666 (0.424 to 1.045)
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All patients 1226 0.758 (0.661 to 0.869)
No prior hypertension 692 0.736 (0.616 to 0.88)
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metastasis <=1
535 0.655 (0.527 to 0.815)
Number of organs with
metastasis >1
691 0.822 (0.69 to 0.979)
No liver metastasis,
or liver and other metastases
927 0.839 (0.719 to 0.98)
Liver metastasis only 299 0.547 (0.413 to 0.725)
Colon/Rectosigmoid/Other 855 0.71 (0.603 to 0.836)
Rectum 371 0.881 (0.689 to 1.127)
Hazard ratio
Hazard ratio
P-value for interaction
P-value for interaction
Age: 0.929
Gender: 0.712
Region: 0.325
Prior hypertension: 0.788
Number of organs
with metastasis: 0.146
Liver metastases
only: 0.008
Location of
primary tumour: 0.153
1
Fig. 3. Forest plots for progression-free survival in planned subgroup analyses by patient demographic (Panel A) and baseline characteristics
(Panel B). p values 60.1 indicate a signiﬁcant interaction between treatment and baseline characteristic subgroup factors at the 2-sided 10% level
(Cox proportional hazard model). HR, hazard ratio.
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Table 1
Baseline characteristics in patients stratiﬁed by prior bevacizumab treatment.
Parameter Prior bevacizumab No bevacizumab
Placebo/FOLFIRI
(n = 187)
Aﬂibercept/FOLFIRI
(n = 186)
Placebo/FOLFIRI
(n = 427)
Aﬂibercept/FOLFIRI
(n = 426)
Eastern Cooperative Oncology Group performance status, n (%)
0 107 (57.2) 107 (57.5) 243 (56.9) 242 (56.8)
1 74 (39.6) 74 (39.8) 176 (41.2) 176 (41.3)
2 6 (3.2) 5 (2.7) 8 (1.9) 8 (1.9)
Male, n (%) 105 (56.1) 110 (59.1) 248 (58.1) 255 (59.9)
Age, y, median (range) 60.0 (27–86) 59.0 (32–81) 61.0 (19–84) 61.0 (21–82)
Prior hypertension, n (%) 97 (51.9) 92 (49.5) 171 (40.0) 174 (40.8)
Region, n (%)
Western Europe 70 (37.4) 54 (29.0) 147 (34.4) 154 (36.2)
Eastern Europe 34 (18.2) 47 (25.3) 102 (23.9) 114 (26.8)
North America 53 (28.3) 49 (26.3) 22 (5.2) 14 (3.3)
South America 8 (4.3) 8 (4.3) 48 (11.2) 54 (12.7)
Other countries 22 (11.8) 28 (15.1) 108 (25.3) 90 (21.1)
Race, n (%)
Caucasian/White 166 (88.8) 172 (92.5) 357 (83.6) 376 (88.3)
Black 7 (3.7) 5 (2.7) 20 (4.7) 11 (2.6)
Asian/Oriental 6 (3.2) 4 (2.2) 45 (10.5) 31 (7.3)
Other 8 (4.3) 5 (2.7) 5 (1.2) 8 (1.9)
Primary tumour location
Colon/rectosigmoid/other 141 (75.4) 140 (75.3) 299 (70.0) 275 (64.6)
Rectum 46 (24.6) 46 (24.7) 128 (30.0) 151 (35.4)
No. of metastatic organs involved at baseline, n (%)
0 1 (0.5) 1 (0.5) 5 (1.2) 1 (0.2)
1 86 (46.0) 80 (43.0) 185 (43.3) 176 (41.3)
>1 100 (53.5) 105 (56.5) 237 (55.5) 249 (58.5)
Metastatic organs involved at baseline, n (%)
Any site 186 (99.5) 185 (99.5) 422 (98.8) 425 (99.8)
Liver 146 (78.1) 146 (78.5) 285 (66.7) 313 (73.5)
Lung 74 (39.6) 87 (46.8) 203 (47.5) 184 (43.2)
Lymph nodes 49 (26.2) 46 (24.7) 132 (30.9) 127 (29.8)
Peritoneum 23 (12.3) 24 (12.9) 65 (15.2) 44 (10.3)
Liver metastasis, n (%)
None, or liver and other metastases 131 (70.1) 134 (72.0) 337 (78.9) 325 (76.3)
Liver metastasis only 56 (29.9) 52 (28.0) 90 (21.1) 101 (23.7)
Duration of bevacizumab use, months,
median (range)
6 (0–28) 6 (0–29) – –
Antiangiogenic-free period, months,
median (range)
2 (1–21) 2 (1–33) – –
Abbreviation: FOLFIRI, 5-ﬂuorouracil, leucovorin and irinotecan.
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ian PFS in patients without prior exposure to bev-
acizumab was 6.9 months in the aﬂibercept arm and
5.4 months in the control arm (Fig. 5).
3.4. Adverse events in patient subgroups
The frequency of TEAEs was generally consistent
across patient subgroups. Table 3 summarises the most
frequently reported grade 3 and grade 4 adverse events
(including those leading to treatment discontinuation),
as well as events typically associated with anti-VEGF
therapy, in patients stratiﬁed by prior bevacizumab
treatment. As previously reported, the use of aﬂiberceptincreased the chemotherapy-related toxicities associated
with FOLFIRI [4]. There was no evidence of greater
toxicity in patients previously treated with bevacizumab
compared with those not previously treated with
bevacizumab. Furthermore, the previous use of
bevacizumab did not increase the rate of anti-VEGF-
associated events.
4. Discussion
Patients with mCRC comprise a heterogeneous pop-
ulation as represented by diﬀerences in variables such as
age, co-morbidities, primary tumour site, extent and
location of metastases, ECOG PS and prior treatment
Table 2
Median overall survival (months) and median progression-free survival (months) and hazard ratio estimates by stratiﬁcation factors.
Overall survival n Placebo/FOLFIRI median
(95.34% CI)
Aﬂibercept/FOLFIRI median
(95.34% CI)
Hazard ratio
(95.34% CI)
p Value for
interaction
All patients 1226 12.1 (11.07–13.11) 13.5 (12.52–14.95) 0.817 (0.713–0.937)
Prior bevacizumab
No 853 12.4 (11.17–13.54) 13.9 (12.71–15.64) 0.788 (0.669–0.927) 0.5668
Yes 373 11.7 (9.82–13.77) 12.5 (10.78–15.51) 0.862 (0.673–1.104)
ECOG PS
0 699 14.1 (12.88–16.62) 16.9 (14.78–18.79) 0.768 (0.635–0.928) 0.7231
1 500 10.1 (9.20–11.53) 10.7 (9.36–12.35) 0.869 (0.71–1.063)
2 27 4.4 (1.97–10.02) 2.8 (0.92–9.82) 0.978 (0.43–2.221)
Progression-free
survival
(95% CI) (95% CI) (95% CI)
All patients 1226 4.7 (4.21–5.36) 6.9 (6.51–7.20) 0.758 (0.661–0.869)
Prior bevacizumab
No 853 5.4 (4.53–5.68) 6.9 (6.37–7.20) 0.797 (0.679–0.936) 0.1958
Yes 373 3.9 (3.02–4.30) 6.7 (5.75–8.21) 0.661 (0.512–0.852)
ECOG PS
0 699 5.4 (4.70–5.82) 7.2 (6.87–8.31) 0.761 (0.633–0.913) 0.6954
1 500 4.1 (3.06–4.47) 5.6 (5.06–6.90) 0.749 (0.607–0.923)
2 27 2.0 (1.51–4.76) 2.7 (0.92–12.88) 0.618 (0.259–1.475)
Abbreviations: CI, conﬁdence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; FOLFIRI, 5-ﬂuorouracil, leucovorin
and irinotecan.
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that the beneﬁt of adding aﬂibercept to FOLFIRI in
patients with mCRC demonstrated in the overall (ITT)
population in the VELOUR study [4] is consistently
observed across a range of prespeciﬁed patient sub-
groups based on demographic variables and baseline
clinical characteristics including stratiﬁcation factors at
randomisation (prior bevacizumab treatment and
ECOG PS).
For OS and PFS, there was no signiﬁcant interaction
at the 10% level between treatment arms and demo-
graphic factors, indicating a consistent beneﬁt of aﬂiber-
cept across age, gender, race and geographical region
subgroups (Figs. 2 and 3). Similarly, there was no signif-
icant interaction between treatment arms and stratiﬁca-
tion by prior exposure to bevacizumab or by ECOG PS
(Table 1; Figs. 4 and 5). However, no conclusions can be
drawn from the HR in patients with an ECOG PS of 2,
because of the small sample size for this stratum (27
patients).
Conducting subgroup analyses based on patients’
baseline characteristics showed a signiﬁcant interaction
between treatment arms and factors only in patients
grouped according to liver metastases (Figs. 2B and
3B). There was a greater aﬂibercept treatment eﬀect in
patients with liver-only metastases at baseline than in
patients with either no liver metastases or liver metasta-
ses plus other organ involvement. The same eﬀect has
been seen in another trial in the second-line setting eval-
uating the role of adding an anti-epidermal growth fac-
tor receptor (EGFR) agent, panitumumab, to
FOLFIRI, this suggesting that this patient populationmay derive more beneﬁt from a more intensive treat-
ment [7]. No signiﬁcant heterogeneity in treatment eﬀect
was detected in patients classiﬁed according to prior
hypertension, the number of metastatic organs involved
and location of the primary tumour.
For the end-points of OS and PFS, all prespeciﬁed
subgroup analyses showed a consistent treatment eﬀect
favouring aﬂibercept over placebo (HR, <1.0).
Since bevacizumab in combination with chemother-
apy is approved for ﬁrst-line treatment for mCRC, it
is important to establish whether exposure to this agent
compromises the eﬃcacy of subsequent therapies that
also target the angiogenic pathway, such as aﬂibercept.
Although the present study was not powered to show
diﬀerences between treatment arms for OS within spe-
ciﬁc subgroups, the absence of a signiﬁcant interaction
between treatment arm and prior bevacizumab treat-
ment (yes or no) showed that the eﬃcacy of aﬂibercept
was not diminished by prior bevacizumab treatment. It
is unknown whether these results reﬂect the broad
anti-angiogenic eﬀect of aﬂibercept, which targets VEG-
FB and PIGF in addition to VEGFA. Nevertheless, this
is an encouraging observation and potentially broadens
the options for those patients surviving ﬁrst-line regi-
mens that include bevacizumab and who are eligible
for further treatment. Further evidence that patients
treated ﬁrst-line with bevacizumab can beneﬁt from sub-
sequent therapies that target VEGF is provided by the
results from the TML study. In this study, patients
who had progressed on bevacizumab in combination
with chemotherapy as ﬁrst-line treatment demonstrated
a signiﬁcant prolongation of OS and PFS when
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Table 3
Adverse events in patients stratiﬁed by prior bevacizumab status according to e-CRFs (safety population).
Adverse eventsa, %
patients
Prior bevacizumab No bevacizumab
Placebo/FOLFIRI (n = 172) Aﬂibercept/FOLFIRI
(n = 171)
Placebo/FOLFIRI
(n = 433)
Aﬂibercept/FOLFIRI
(n = 440)
Serious AEs 32 52 33 47
Fatal AE b due to PD 3 2 2 2
Fatal AE b in other
context than PD
2 2 1 3
Grade 3 Grade 4 Grade 3 Grade 4 Grade 3 Grade 4 Grade 3 Grade 4
Grade 3/4 AEs in >10% of patients in any treatment group
Neutropenia (PT) 9.3 4.1 13.5 6.4 17.1 8.3 18.0 9.1
Diarrhoea (PT) 8.1 0.6 18.1 0.6 7.4 0 19.3 0.2
Infections and infestations
(SOC)
6.4 1.2 12.9 0.6 6.0 0.7 10.2 1.6
Stomatitis (PT) 3.5 0 10.5 0 5.1 0 13.4 0.2
Hypertension (PT) 0.6 0 16.4 0 1.8 0 20.0 0.2
Fatigue (PT) 8.7 0 14.6 0 7.2 0.2 10.9 0.9
Other anti-VEGF-associated events
Proteinuria 0.6 0 9.4 0 1.4 0 7.3 0
Haemorrhage 1.2 0 3.5 0 1.8 0 2.5 0.2
GI disorders (SOC) 0.6 0 3.5 0 1.2 0 1.1 0.2
Headache (PT) 0 0 0.6 0 0.5 0 2.0 0
Venous thromboembolic
event
2.9 2.9 4.7 2.3 2.5 3.9 2.5 5.7
Pulmonary embolism
(PT)
0 2.9 0 2.3 0 3.7 0 5.5
Arterial thromboembolic
event
0.6 0 0.6 1.2 0.5 0 0.9 0.9
GI perforation 0 0 0 0 0.2 0.2 0.2 0.5
AEs leading to permanent treatment discontinuation
Any 9.3 25.7 13.2 27.3
Grade 3/4 in >1% of
patients
Grade 3/4 Grade 3/4 Grade 3/4 Grade 3/4
Fatigue 0.6 1.8 0.7 1.8
Diarrhoea 0.6 1.8 0.2 1.8
Hypertension 0 0 0 2.3
Pulmonary embolism 0 0.6 1.6 1.4
Asthenia 0 0.6 0.2 1.4
Dehydration 0 1.2 0.2 0.7
Rectal haemorrhage 0 1.2 0 0
Neutropenic infection 1.2 0 0 0.5
Abbreviations: AE, adverse event; e-CRF, electronic case report form; FOLFIRI, ﬂuorouracil, leucovorin and irinotecan; PD, progressive disease;
PT, preferred term; SOC, system organ class.
a Grades were determined according to NCI-CTCAE, version 3.0.
b Deaths within 30 days of last treatment dose.
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ﬁrst-line treatment) therapy was continued beyond pro-
gression [8].
As previously reported for this study and consistent
with other clinical studies of aﬂibercept [4,9], aﬂibercept
in combination with FOLFIRI was associated with a
safety proﬁle expected for the addition of an anti-VEGF
agent to chemotherapy and no new toxicity signals were
observed [4]. The present analysis suggests that this pro-
ﬁle was not markedly impacted upon by prior treatment
with bevacizumab.
In conclusion, the signiﬁcant improvement in OS and
PFS when aﬂibercept is added to FOLFIRI in the treat-
ment of mCRC patients previously treated with anoxaliplatin-based regimen is robust, with consistency
across demographic and baseline characteristics and
stratiﬁcation factors at randomisation. Eﬃcacy was
maintained, with a similar safety proﬁle, irrespective of
prior treatment with bevacizumab. Aﬂibercept has the
potential to provide a new therapeutic option in the
treatment of mCRC previously treated with an oxalipl-
atin regimen.
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